Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Prime Medicine, Inc. | 39,062 | reported | 01 Aug 2025 | tx 7+223,124−84,062 |
| Foundation Medicine, Inc. | 23,326 | reported | 16 Jun 2016 | tx 13+93,957−403,642 |
| Denali Therapeutics Inc. | 18,111 | reported | 03 Jun 2025 | tx 34+518,214−439,857 |
| AGIOS PHARMACEUTICALS, INC. | 11,774 | reported | 20 Jun 2024 | tx 267+2,083,584−2,066,544 |
| bluebird bio, Inc. | 5,332 | reported | 18 Jun 2020 | tx 21+48,832−14,000 |
| REGENERON PHARMACEUTICALS, INC. | 603 | reported | 02 Jan 2026 | tx 8+7,770 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 02 Jan 2026 | GRANT_AWARD | REGENERON PHARMACEUTICALS, INC. | 155 | 0.00 USD | |
| 02 Jan 2026 | GRANT_AWARD | REGENERON PHARMACEUTICALS, INC. | 1,962 | 0.00 USD | deriv |
| 01 Aug 2025 | GRANT_AWARD | Prime Medicine, Inc. | 45,000 | — | deriv |
| 01 Aug 2025 | GRANT_AWARD | Prime Medicine, Inc. | 39,062 | — | deriv |
| 01 Aug 2025 | OTHER | Prime Medicine, Inc. | 39,062 | — | deriv |
| 01 Aug 2025 | OTHER | Prime Medicine, Inc. | 45,000 | — | deriv |
| 03 Jun 2025 | GRANT_AWARD | Denali Therapeutics Inc. | 6,037 | 0.00 USD | |
| 03 Jun 2025 | GRANT_AWARD | Denali Therapeutics Inc. | 18,111 | 0.00 USD | deriv |
| 04 Jun 2025 | GRANT_AWARD | Prime Medicine, Inc. | 55,000 | 0.00 USD | deriv |
| 02 Jan 2025 | GRANT_AWARD | REGENERON PHARMACEUTICALS, INC. | 166 | 0.00 USD | |
| 02 Jan 2025 | GRANT_AWARD | REGENERON PHARMACEUTICALS, INC. | 1,958 | 0.00 USD | deriv |
| 11 Nov 2024 | EXERCISE | Denali Therapeutics Inc. | 47,165 | 18.00 USD | |
| 11 Nov 2024 | SALE | Denali Therapeutics Inc. | 27,129 | 32.09 USD | |
| 11 Nov 2024 | SALE | Denali Therapeutics Inc. | 32,312 | 32.87 USD | |
| 11 Nov 2024 | EXERCISE | Denali Therapeutics Inc. | 47,165 | 0.00 USD | deriv |
| 20 Jun 2024 | GRANT_AWARD | AGIOS PHARMACEUTICALS, INC. | 11,774 | 0.00 USD | deriv |
| 20 Jun 2024 | GRANT_AWARD | AGIOS PHARMACEUTICALS, INC. | 2,120 | 0.00 USD | deriv |
| 13 Jun 2024 | EXERCISE | AGIOS PHARMACEUTICALS, INC. | 3,388 | 0.00 USD | |
| 13 Jun 2024 | EXERCISE | AGIOS PHARMACEUTICALS, INC. | 3,388 | 0.00 USD | deriv |
| 12 Jun 2024 | GRANT_AWARD | Prime Medicine, Inc. | 45,000 | 0.00 USD | deriv |
| 31 May 2024 | GRANT_AWARD | Denali Therapeutics Inc. | 5,967 | 0.00 USD | |
| 31 May 2024 | GRANT_AWARD | Denali Therapeutics Inc. | 17,901 | 0.00 USD | deriv |
| 27 Feb 2024 | SALE | AGIOS PHARMACEUTICALS, INC. | 11,858 | 33.60 USD | |
| 27 Feb 2024 | SALE | AGIOS PHARMACEUTICALS, INC. | 57,471 | 34.89 USD | |
| 27 Feb 2024 | EXERCISE | AGIOS PHARMACEUTICALS, INC. | 11,858 | 31.64 USD |
1 purchase reported after at least 12 months of silence — most recent on 13 Nov 2019.